Adverse Pregnancy Outcomes and Maternal Chronic Diseases in the Future: a Cross-sectional Study Using KoGES-HEXA Data

Geum Joon Cho

Department of Obstetrics and Gynecology, College of Medicine, Korea University

Jiae Kim

Department of Obstetrics and Gynecology, College of Medicine, The Catholic University of Korea

Ji Young Kim

Department of Obstetrics and Gynecology, College of Medicine, The Catholic University of Korea

Sung Won Han

School of Industrial Management Engineering, Korea University

Soo Bin Lee

School of Industrial Management Engineering, Korea University

Min-Jeong Oh

Department of Obstetrics and Gynecology, College of Medicine, Korea University

Sa Jin Kim

Department of Obstetrics and Gynecology, College of Medicine, The Catholic University of Korea

Jae Eun Shin (✉ jennie1008@catholic.ac.kr)

Catholic University of Korea <https://orcid.org/0000-0002-8326-8541>

Research Article

Keywords: metabolic syndrome, preeclampsia, gestational diabetes mellitus, low birth weight, macrosomia, cardiovascular disease

Posted Date: December 13th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-1062386/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Journal of Clinical Medicine on March 7th, 2022. See the published version at <https://doi.org/10.3390/jcm11051457>.

Abstract

Purpose Adverse pregnancy outcomes (APOs) are associated with an increased risk of chronic diseases, including cardiovascular disease (CVD) and metabolic syndrome (MS), in the future. We designed a large-scale cohort study to evaluate the influence of APOs (preeclampsia, gestational diabetes mellitus [GDM], stillbirth, macrosomia, and low birth weight) on the incidence of chronic diseases, body measurements, and serum biochemistry in the future and investigate whether combinations of APOs had additive effects on chronic diseases.

Methods We used health examinee data from the Korean Genome and Epidemiology Study (KoGES-HEXA) and extracted data of parous women ($n = 30,174$; mean age, 53.02 years) for the analysis. A logistic regression model was used to estimate adjusted odds ratios (aORs) and 95% confidence intervals.

Results The prevalence rate of APOs was 17.4% (5,264 women). Univariate analysis revealed that women with APOs were more frequently diagnosed with chronic diseases and had a family history of chronic diseases compared with women without APOs. In logistic regression analysis, composite APOs were associated with an increased risk of hypertension, diabetes mellitus, hyperlipidemia, angina pectoris, stroke, and MS (aOR: 1.093, 1.379, 1.269, 1.351, 1.414, and 1.104, respectively), after adjustment for family history and social behaviors. Preeclampsia and GDM were associated with an increased risk of some chronic diseases; however, the combination of preeclampsia and GDM did not have an additive effect on the risk.

Conclusion APOs moderately influenced the future development of maternal CVD and metabolic derangements, independent of family history and social behaviors.

Introduction

Chronic diseases, including cardiovascular disease (CVD) and its risk factors such as diabetes mellitus and metabolic syndrome (MS), are now recognized as the leading factors that threaten women's health worldwide. Prevalence rates of both coronary heart disease (CHD) and stroke have risen to similar levels as those of men of a similar age [1, 2]. CHD mortality rates have increased in American women within the age range of 35–54 years, contrary to a decreasing trend in the past four decades from 1980 to 2000 [1, 3, 4]. Additionally, in Korea, the CVD mortality rate is even 1.1 times higher in women than that in men [5]. These suggest that underlying factors leading to CVD may be different in women compared with men, and identification of pathophysiology unique to women has considerable potential to improve the long-term health status of women.

With an improved understanding of cardiovascular changes during normal pregnancy and the changes that are associated with adverse pregnancy outcomes (APOs), it is now recognized that obstetric events can contribute to gender-specific differences in cardiovascular risk and the development of CVD later in life [6]. APOs have also been linked to MS, a major risk factor for CVD [7, 8]. Guidelines for the prevention

of CVD in women include a history of APOs, such as preeclampsia, gestational diabetes mellitus (GDM), preterm delivery, pregnancy-induced hypertension, and delivery of a low birth weight (LBW) infant as major CVD risk factors [1, 9–11]. The link between APOs and future chronic diseases mainly focuses on preeclampsia and GDM. Many epidemiologic studies and meta-analyses have shown that preeclampsia is related to an increased risk of developing or dying from overall CVD [12–14]. Moreover, preeclampsia is positively associated with cardiovascular risk factors such as hypertension, diabetes mellitus, and MS [12, 15–17]. GDM is also associated with a significant increase in the risk factors for CVD, including diabetes mellitus and hypertension [18–20]. However, other APOs, such as macrosomia, LBW, and stillbirth, have not been extensively studied. Furthermore, whether APOs cause various chronic diseases and affect serum biochemistry in later life and whether a combination of APOs confers higher risks of chronic diseases need to be investigated. Additionally, many studies have failed to adjust for factors such as social behaviors and family history of cardiometabolic status, thus limiting the understanding of CVD risk trajectory.

We, therefore, designed a large-scale cohort study to (1) evaluate the influence of APOs (preeclampsia, GDM, stillbirth, macrosomia, LBW) on the incidence of chronic diseases, body measurements, and serum biochemistry in later life, (2) assess whether APOs were independent risk factors for chronic diseases, and (3) investigate the additive effects of combinations of APOs on chronic diseases.

Methods

Study Population and design

This cohort study relied on data from the Korean Genome and Epidemiology Study (KoGES). The KoGES is a national survey conducted by the Korean government (National Research Institute of Health, Centers for Disease Control and Prevention, and Ministry for Health and Welfare, Republic of Korea) to investigate the genetic and environmental etiology of common complex diseases in Koreans and causes of death. Details of the KoGES and the methods used were comprehensively explored [21]. Among the KoGES Consortium data, we used KoGES health examinee (HEXA) data consisting of data from participants older than 40 years who resided in urban areas. The HEXA cohort included participants from examination centers/medical institutions of 14 major cities across Korea who were recruited between 2004 and 2013. All participants voluntarily signed an informed consent form and attended follow-up from 2012 to 2016. This study was approved by the Ethics Committee of Korea University (2021GR0007).

Participant Selection

Among 113,945 women, women who lacked records of pregnancy outcome histories ($n = 25,803$), who lacked records of previous medical history, including family history ($n = 57,808$), and with a history of CVD before pregnancy ($n = 139$) were excluded. Finally, 30,174 participants were included in the study.

Survey

The HEXA consisted of two components: a health interview and a health examination. The health interview included questions regarding demographics, lifestyle status, medical history, and pregnancy outcomes. Each participant was asked regarding the previous history of pregnancy outcomes, including preeclampsia, GDM, stillbirth, macrosomia (birth weight of the neonate ≥ 4 kg), and LBW (birth weight of the neonate ≤ 2.5 kg), by trained interviewers. Each participant was also asked regarding the medical history of chronic diseases (hypertension, diabetes mellitus, hyperlipidemia, stroke, transient cerebral ischemia, angina pectoris, and Parkinson's disease) and family history of chronic diseases. Data for the following covariates were also obtained: age, age at delivery, lactation history, alcohol consumption, and smoking status. Smoking status was divided into two categories: current smoker and non-smoker. Drinking status was also classified into two groups: current drinker and non-drinker.

The health examination included anthropometric measurements and serum laboratory tests. All anthropometric measurements were obtained by trained and skilled examiners using a consistent and standardized methodology. Height was measured to the nearest 1 mm using a portable extensimeter (SECA 225; SECA, Hamburg, Germany). Weight was measured to the nearest 0.1 kg using a calibrated balance scale (GL-6000-20; CAS KOREA, Seoul, Korea). Waist circumference (WC) was measured at the narrowest point between the lower border of the rib cage and the iliac crest during minimal respiration. Hip circumference (HC) was measured at the widest part of the hip in the horizontal plane. Blood pressure (BP) was measured using a standard mercury sphygmomanometer.

All blood samples were obtained after the participants had fasted for a minimum of eight hours. The levels of fasting blood sugar (FBS), γ -glutamyl transferase, aspartate aminotransferase, alanine aminotransferase, albumin, blood urea nitrogen, creatinine, uric acid, total cholesterol, high-density lipoprotein cholesterol (HDL-C), triglycerides, and high-sensitivity C-reactive protein were measured using enzymatic methods.

Covariates

Composite APOs were defined if any of the APOs was present. MS was defined using the criteria proposed by the Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention [22]. MS was defined as the presence of at least three of the five metabolic components described as follows: (i) a WC ≥ 80 cm, according to the International Diabetes Federation criteria for Asian countries; (ii) FBS ≥ 100 mg/dL or treatment for elevated glucose; (iii) serum fasting triglyceride ≥ 150 mg/dL (1.7 mmol/L) or medication use; (iv) serum HDL-C < 50 mg/dL (1.3 mmol/L) or medication use; and (v) systolic BP ≥ 130 mmHg, diastolic BP ≥ 85 mmHg, or drug treatment for hypertension.

Statistical analysis

Continuous and categorical variables are expressed as mean $\pm$ standard deviation and percentages, respectively. Basic characteristics, body measurements, and serum biochemistry of the study population were compared between women with APOs and women without APOs, using t-test for continuous

variables and chi-square test for categorical variables. Multivariate logistic regression analysis was used to estimate the adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for the development of chronic diseases. For multivariable analyses, we adjusted for maternal age, family history (hypertension, diabetes, angina, and stroke), present smoking, and present alcohol consumption. The significance level was defined as a p-value less than 0.05. Statistical analyses were performed using SAS for Windows (version 9.4; SAS Inc., Cary, NC, USA).

Results

APOs occurred in 5,264 women in the study population (prevalence rate, 17.4%), and the mean age of the participants was 53.02 years. The characteristics of the study participants are listed in Table 1. Women with APOs had lower age (51.70 ± 7.68 vs. 53.42 ± 8.08 years, $p < 0.001$) but had higher age at first delivery (25.81 ± 3.00 vs. 25.32 ± 3.01 years, $p < 0.001$) and last delivery (30.22 ± 3.84 vs. 29.75 ± 3.67 years, $p < 0.001$) than women without APOs. Compared with those without APOs, those with APOs were more frequently diagnosed with some chronic diseases such as diabetes mellitus and hypercholesterolemia and had a family history of chronic diseases, including hypertension, diabetes mellitus, angina pectoris, and stroke. They were also more likely to smoke and drink alcohol and less likely to breastfeed. Prevalence rates of MS and its components were not statistically different between the two groups, except in women with high FBS levels.

Table 1
The characteristics of the study population

	Women without APOs (n = 24,910)	Women with APOs (n = 5,264)	p-value
Baseline characteristics			
Age, y	53.31 ± 8.27	51.70 ± 7.56	<0.001
Age of first delivery, y	25.09 ± 2.95	25.65 ± 2.92	<0.001
Age of last delivery, y	29.88 ± 3.69	30.21 ± 3.78	<0.001
Chronic diseases			
Hypertension	4537 (18.21)	942 (17.90)	0.586
Diabetes	1267 (5.09)	314 (5.97)	0.009
Hyperlipidemia	1549 (6.22)	381 (7.24)	0.006
Stroke	275 (1.10)	71 (1.35)	0.130
Transient cerebral ischemia	41 (0.16)	6 (0.11)	0.398
Angina pectoris	463 (1.86)	110 (2.09)	0.265
Parkinson's disease	20 (0.08)	3 (0.06)	0.659
Family history of chronic diseases			
Hypertension	6410 (25.73)	1672 (31.76)	<0.001
Diabetes	3737 (15.00)	1011 (19.21)	<0.001
Stroke	3378 (13.56)	848 (16.11)	<0.001
Angina pectoris	1558 (6.25)	415 (7.88)	<0.001
Behavioral variables			
Current smoking	581 (2.33)	148 (2.81)	0.040
Current alcohol drinking	7381 (29.63)	1652 (31.38)	0.012

Data are presented as mean ± standard error or n (%).

APOs adverse pregnancy outcomes; *BP* blood pressure; *FBS* fasting blood sugar; *TG* total triglyceride; *HDL-C* high-density lipoprotein cholesterol.

^aComponents: abdominal obesity was defined as a waist circumference ≥80 cm. Elevated BP was defined as systolic/diastolic pressure ≥130/85 mm Hg or drug treatment for hypertension. Elevated FBS was defined as FBS level ≥100 mg/dL or treatment for elevated glucose. High TG were defined as TG ≥150 mg/dL or medication use. Low HDL-C was defined as an HDL-C level <50 mg/dL or medication use.

	Women without APOs (n = 24,910)	Women with APOs (n = 5,264)	p-value
Lactation history			
Lactation	22715 (91.19)	4651 (88.35)	<0.001
Sibling number of lactations	2.55 ± 1.07	2.35 ± 0.91	<0.001
Duration of lactation, m	31.40 ± 28.65	26.52 ± 22.38	<0.001
Metabolic syndrome and its components ^a			
Metabolic syndrome	5018 (20.14)	1023 (19.43)	0.242
Abdominal obesity alone	6710 (26.94)	1455 (27.64)	0.297
Elevated BP alone	9986 (40.09)	2064 (39.21)	0.237
Elevated FBS alone	5752 (23.09)	1314 (24.96)	0.004
High TG alone	5432 (21.81)	1110 (21.09)	0.250
Low HDL-C alone	7452 (29.92)	1519 (28.86)	0.127
Data are presented as mean ± standard error or n (%).			
<i>APOs</i> adverse pregnancy outcomes; <i>BP</i> blood pressure; <i>FBS</i> fasting blood sugar; <i>TG</i> total triglyceride; <i>HDL-C</i> high-density lipoprotein cholesterol.			
^a Components: abdominal obesity was defined as a waist circumference ≥80 cm. Elevated BP was defined as systolic/diastolic pressure ≥130/85 mm Hg or drug treatment for hypertension. Elevated FBS was defined as FBS level ≥100 mg/dL or treatment for elevated glucose. High TG were defined as TG ≥150 mg/dL or medication use. Low HDL-C was defined as an HDL-C level <50 mg/dL or medication use.			

Body measurements and laboratory data were also compared between the two groups (Table 2). Women with APOs had greater height, weight, WC, and HC than women without APOs. Mean values of FBS and serum albumin levels were statistically different between the two groups.

Table 2
The body measurements and laboratory data of the study population

	Women without APOs (n = 24,910)	Women with APOs (n = 5,264)	p-value
Body measurements			
Height, cm	155.65 ± 5.28	156.53 ± 5.23	<0.001
Weight, Kg	57.82 ± 7.36	59.17 ± 7.88	<0.001
WC, cm	79.73 ± 8.03	80.05 ± 8.20	0.009
HC, cm	94.37 ± 5.54	94.95 ± 5.74	<0.001
PR	67.82 ± 9.46	67.49 ± 9.61	0.032
Systolic BP, mmHg	121.93 ± 16.42	121.41 ± 16.12	0.035
Diastolic BP, mmHg	75.86 ± 10.09	75.79 ± 10.17	0.630
Laboratory findings			
FBS, mg/dL	93.21 ± 19.65	94.62 ± 24.61	<0.001
GGT	21.56 ± 22.67	21.59 ± 21.36	0.917
AST	23.11 ± 14.12	22.90 ± 13.60	0.320
ALT	20.16 ± 17.50	20.31 ± 24.04	0.666
Albumin	4.63 ± 0.28	4.64 ± 0.28	0.010
BUN	13.66 ± 3.78	13.56 ± 3.77	0.058
Creatinine	0.77 ± 0.18	0.77 ± 0.14	0.297
Uric acid	4.25 ± 0.97	4.28 ± 0.96	0.063
TC, mg/dL	199.56 ± 35.51	199.13 ± 35.60	0.428
HDL-C, mg/dL	56.92 ± 12.74	57.14 ± 12.68	0.259
TG, mg/dL	115.60 ± 76.05	113.51 ± 75.66	0.070
hsCRP	0.13 ± 0.37	0.14 ± 0.33	0.784
Data are presented as mean ± standard error or n (%).			
<i>WC</i> waist circumference; <i>HC</i> hip circumference; <i>PR</i> pulse rate; <i>BP</i> blood pressure; <i>FBS</i> fasting blood sugar; <i>GGT</i> γ-glutamyl transferase; <i>AST</i> aspartate aminotransferase; <i>ALT</i> alanine aminotransferase; <i>BUN</i> blood urea nitrogen ; <i>TC</i> total cholesterol ; <i>HDL-C</i> high-density lipoprotein cholesterol; <i>TG</i> total triglyceride; <i>hsCRP</i> high sensitivity C-reactive protein.			

Table 3 presents the results of the multiple regression analysis from the model used to investigate the relationship between previous APOs and chronic diseases. After adjusting for confounding factors, women with composite APOs showed higher rates of hypertension (aOR, 1.093; 95% CI, 1.004–1.189), diabetes mellitus (aOR, 1.379; 95% CI, 1.207–1.575), hyperlipidemia (aOR, 1.269; 95% CI, 1.126–1.429), stroke (aOR, 1.414; 95% CI, 1.083–1.847), and angina pectoris (aOR, 1.351; 95% CI, 1.090–1.675) than those without APOs. Transient cerebral ischemia was not associated with composite APOs. Women with preeclampsia only had a higher risk of hypertension, hyperlipidemia, and angina pectoris. Women with GDM only had a higher risk of hypertension, diabetes mellitus, and hyperlipidemia. The risk estimate of GDM for future diabetes mellitus was the highest (aOR, 9.069; 95% CI, 5.938–13.851). In women with a combination of preeclampsia and GDM, the association was significant only with diabetes mellitus (aOR, 3.287; 95% CI, 1.473–7.338), and the association was not additive. Maternal risk of chronic diseases was not associated with stillbirth or LBW among the APOs. Macrosomia was associated with a higher risk of diabetes mellitus and hyperlipidemia, a trend that was similar to that of GDM.

Table 3
Logistic regression analysis for APOs for predicting chronic disease

	Hypertension	Diabetes mellitus	Hyperlipidemia	Transient ischemia	Stroke	Angina pectoris
	aOR (95% CI)	aOR (95% CI)	aOR (95% CI)	aOR (95% CI)	aOR (95% CI)	aOR (95% CI)
Composite APOs	1.093 (1.004, 1.189)	1.379 (1.207, 1.575)	1.269 (1.126, 1.429)	0.685 (0.289, 1.622)	1.414 (1.083, 1.847)	1.351 (1.090, 1.675)
Preeclampsia	1.394 (1.215, 1.599)	0.988 (0.775, 1.260)	1.194 (0.976, 1.461)	1.324 (0.406, 4.318)	1.313 (0.842, 2.048)	1.429 (1.012, 2.019)
GDM	1.417 (0.974, 2.061)	6.640 (4.549, 9.693)	1.665 (1.024, 2.707)	-	1.092 (0.266, 4.477)	0.671 (0.164, 2.739)
Stillbirth	0.944 (0.680, 1.310)	0.953 (0.563, 1.613)	0.725 (0.426, 1.234)	-	1.597 (0.700, 3.645)	0.753 (0.306, 1.851)
Macrosomia	0.881 (0.780, 0.995)	1.573 (1.325, 1.867)	1.273 (1.083, 1.496)	0.250 (0.034, 1.817)	1.434 (1.000, 2.058)	1.292 (0.959, 1.741)
LBW	1.093 (0.938, 1.273)	0.884 (0.667, 1.171)	1.200 (0.966, 1.491)	1.405 (0.431, 4.582)	1.383 (0.862, 2.218)	1.276 (0.863, 1.886)
Preeclampsia only	1.409 (1.227, 1.618)	1.111 (0.869, 1.422)	1.290 (1.055, 1.578)	1.303 (0.403, 4.214)	1.446 (0.933, 2.244)	1.466 (1.036, 2.074)
GDM only	1.593 (1.011, 2.511)	9.069 (5.938, 13.851)	2.496 (1.484, 4.198)		1.918 (0.469, 7.854)	0.566 (0.078, 4.085)
Preeclampsia + GDM	1.579 (0.834, 2.991)	3.287 (1.473, 7.338)	0.559 (0.136, 2.298)			1.263 (0.173, 9.224)
Adjusted by age, family history (hypertension, diabetes, angina, stroke), present smoking, and present alcohol.						
<i>aOR</i> adjusted odds ratio; <i>CI</i> confidence interval; <i>APOs</i> adverse pregnancy outcome; <i>GDM</i> gestational diabetes; <i>LBW</i> low birth weight.						
The unadjusted basic model is described in supplementary Table S1.						

We analyzed the relationship between APOs and future MS and its components (Table 4). Adjusted analysis showed that composite APOs were associated with an increased risk of MS (aOR, 1.104; 95% CI,

1.020–1.194), elevated WC (aOR, 1.172; 95% CI, 1.094–1.255), hypertension (aOR, 1.074; 95% CI, 1.006–1.147), and elevated FBS level (aOR, 1.193; 95% CI, 1.111–1.280). Low HDL and high triglyceride levels were not associated with composite APOs. The effect of preeclampsia only on MS was not statistically significant; however, the effects of GDM only and the combination of preeclampsia and GDM on MS were statistically significant (aOR, 1.908 and 1.866, respectively). The combination of APOs reduced the risk of MS rather than increasing it.

Table 4
Logistic regression analysis for APOs for predicting metabolic syndrome and its components

	Metabolic syndrome	Abdominal obesity	Elevated BP	Elevated FBS	Low HDL-C	High TG
	aOR (95% CI)	aOR (95% CI)	aOR (95% CI)	aOR (95% CI)	aOR (95% CI)	aOR (95% CI)
Composite APOs	1.104 (1.020, 1.194)	1.172 (1.094, 1.255)	1.074 (1.006, 1.147)	1.193 (1.111, 1.280)	1.009 (0.944, 1.078)	1.038 (0.964, 1.118)
Preeclampsia	1.115 (0.974, 1.276)	1.185 (1.051, 1.335)	1.349 (1.204, 1.510)	1.040 (0.916, 1.179)	0.939 (0.835, 1.057)	1.001 (0.879, 1.141)
GDM	1.814 (1.309, 2.515)	1.300 (0.959, 1.763)	1.372 (1.034, 1.821)	2.512 (1.907, 3.310)	1.210 (0.908, 1.613)	1.281 (0.929, 1.766)
Stillbirth	1.015 (0.747, 1.379)	1.025 (0.774, 1.356)	1.133 (0.862, 1.488)	1.029 (0.770, 1.376)	0.969 (0.735, 1.276)	1.111 (0.830, 1.487)
Macrosomia	1.098 (0.986, 1.223)	1.350 (1.231, 1.479)	0.888 (0.811, 0.972)	1.297 (1.180, 1.426)	1.042 (0.952, 1.141)	1.001 (0.903, 1.109)
LBW	0.956 (0.824, 1.108)	0.824 (0.721, 0.941)	1.060 (0.942, 1.193)	0.926 (0.809, 1.059)	0.973 (0.862, 1.099)	1.090 (0.954, 1.245)
Preeclampsia only	1.124 (0.980, 1.289)	1.176 (1.042, 1.328)	1.367 (1.219, 1.532)	1.076 (0.947, 1.223)	0.955 (0.847, 1.076)	1.002 (0.878, 1.144)
GDM only	1.908 (1.286, 2.831)	1.209 (0.827, 1.765)	1.511 (1.075, 2.125)	3.001 (2.167, 4.157)	1.396 (0.997, 1.954)	1.207 (0.813, 1.791)
Preeclampsia + GDM	1.866 (1.064, 3.270)	1.817 (1.104, 2.991)	1.532 (0.940, 2.494)	1.848 (1.121, 3.048)	0.810 (0.469, 1.397)	1.468 (0.857, 2.516)
Adjusted by age, family history (hypertension, diabetes, angina, stroke), present smoking, and present alcohol.						
<i>BP</i> blood pressure; <i>FBS</i> fasting blood sugar; <i>HDL-C</i> high-density lipoprotein cholesterol; <i>TG</i> triglyceride; <i>aOR</i> adjusted odds ratio; <i>CI</i> confidence interval; <i>APO</i> adverse pregnancy outcome; <i>GDM</i> gestational diabetes; <i>LBW</i> low birth weight.						
The unadjusted basic model is described in supplementary Table S2.						

Discussion

In this large cohort study, an association was found between APOs and subsequent risk of CVD and other cardiovascular risk factors, including MS, after adjusting for family history of chronic diseases and social behaviors. The risk of CVD and cardiovascular risk factors did not increase further when preeclampsia occurred in combination with GDM.

Similar to previous studies, our study showed that women with APOs were associated with a higher risk of CVD as well as cardiovascular risk factors, including MS. Moreover, women with APOs had a higher prevalence of CVD in the family, which is known as an important risk factor for developing CVD [23–25]. Although family history plays an important role in the development of CVD, a few large cohort studies have adjusted for family history to assess the correlation between APOs and the occurrence of CVD in later life. The increased risk of CVD attributable to family history can be caused by shared genetic, environmental, and behavioral factors [23]. The association between APOs and CVD remaining after adjustment for family history may also be intervened, in part, by maternal environmental and behavioral factors, which could be modifiable. In this study, women with APOs tended to be more obese and had bad habits for cardiometabolic health, especially smoking, alcohol consumption, and less frequent breastfeeding. A previous study also reported that people with a family history of CVD had less favorable risk factors, including physical inactivity and hypercholesterolemia [23]. In this study, we observed a modest but independent association between APOs and the occurrence of CVD in the future after adjusting for family history and social behaviors. Therefore, pregnancy could be a new opportunity to inform women at risk in advance of danger signals and to prevent the occurrence of CVD through lifestyle modifications.

Among the various APOs, preeclampsia and GDM are the most studied to clarify the relationship with chronic diseases. During pregnancy, GDM increases the risk of preeclampsia [26]. However, the combined effect of preeclampsia and GDM on maternal chronic diseases after delivery has not been extensively studied. Only two studies have investigated the combined effects of GDM and preeclampsia on chronic diseases. One study in Canada reported that having both APOs was associated with more than an additive effect on diabetes mellitus, hypertension, and CVD when compared with having neither GDM nor preeclampsia after six months of delivery [27]. Furthermore, a recent study with a small population that was conducted in Turkey also proved that patients with a combination of GDM and preeclampsia had a higher prevalence of CHD than patients with only GDM [28]. Unlike these previous studies, the present study failed to prove the additive effect of the combination of GDM and preeclampsia on chronic diseases. This may be due to differences in the study population and the duration of the follow-up period. One of these previous studies [27] had a limitation in that it was comprised of women with various ethnocultural backgrounds, and the other study [28] had the limitation of a small sample size. Moreover, these studies had a shorter follow-up period of CVD evaluation after delivery than that in the present study. To the best of our knowledge, the present study is the only study that has examined the long-term effect of the combination of preeclampsia and GDM on chronic diseases in a large sample.

Research regarding the long-term health status of women who deliver infants with LBW or macrosomia or have a history of stillbirth is scarce. We observed that macrosomia was associated with an increased risk

of some chronic diseases. This observation may be related to the strong association between macrosomia and GDM, as both groups showed similar results in this study. A previous nationwide Swedish study also reported similar results that the risk of CVD in women giving birth to infants with macrosomia was attenuated after adjusting for cardiometabolic risk factors [29]. Previous studies have shown various results in women who deliver infants with LBW and have a history of stillbirth. In some cohort studies, women who delivered infants with LBW were found to be approximately twice as likely to have CVD in the future [29, 30]. In a recent meta-analysis, associations for composite CVD were two-fold for stillbirth, but no association was noted for LBW or small-for-gestational age [31]. Another meta-analysis reported that women with a history of miscarriage and/or stillbirth were more likely to develop CHD, but not stroke, compared with women without a similar history [32]. These various results could be due to the intervening by genetic and racial factors. A study on the association between stillbirth and all-cause mortality according to nationality and race reported that only in women of North African origin, the adjusted hazard ratio for all-cause mortality after stillbirth had increased significantly, whereas other groups showed no statistically significant differences [33]. Another reason could be that previous studies used different definitions for “a small fetus” and “stillbirth” and had different endpoints of the study, including prevalence and mortality. Further large-scale studies on the relationship between APOs and CVD according to racial and national differences are needed.

Our study has some limitations. The greatest limitation of this study is its cross-sectional design, which does not allow the assessment of the causal pathway underlying the observed relationships. Furthermore, it is possible that there was misclassification and under-reporting of diagnosis because diagnoses of diseases were self-reported by the participants. Additionally, selection bias might have occurred. The subjects were recruited from health examination centers and hospitals located in urban areas of Korea, and only those willing to participate were enrolled; therefore, they might not be entirely representative of the Korean population. This type of screening bias has been observed in many prospective cohort studies. Finally, there was insufficient information on factors that could influence the occurrence of chronic diseases, such as the period from childbirth to the study period, changes in diet or socioeconomic environment from childbirth to the study period, and hormone therapy. No information was available regarding the specific states of pregnancy, including the severity of pregnancy complications, gestational weight gain, and postpartum weight retention. Therefore, although we could adjust for many confounders in the present study, the potential for residual confounding by environmental factors remained. Despite these limitations, our study has several strengths. To the best of our knowledge, this was the only study that had examined the long-term effect of the combination of preeclampsia and GDM on various types of chronic diseases. Moreover, this study had a large sample size, and we were able to adjust for several potential confounders, including family history and social behaviors, and assess their independent and additive effects on the risk of CVD later in life.

In conclusion, APOs moderately influenced the future development of maternal CVD and metabolic derangements, independent of family history and social behaviors. Moreover, the risk of CVD and cardiovascular risk factors did not increase further when preeclampsia occurred in combination with

GDM. Further prospective studies are needed to clarify the relationship between APOs and maternal CVD in the future.

Declarations

Acknowledgments

The authors thank all the participants of this study. In addition, we would like to thank Editage (www.editage.cn) for English language editing.

Funding

Not applicable

Conflict of interest

The authors declare that they have no conflict of interest.

Availability of data and material

The data in this article are obtained from public databases that are open and transparent.

Author's contributions

GJC: Data collection, data analysis, manuscript writing/editing. JK: Data collection, data analysis. JYK: Data collection, data analysis. SWH: Protocol development, statistical analysis. SBL: Protocol development, statistical analysis. MJO: Data collection, data analysis. SJK: Data collection, data analysis. JES: Data analysis, manuscript writing/editing. All authors reviewed and approved the final manuscript.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of Korea University (2021GR0007).

Consent to participate

All participants voluntarily sign an informed consent form.

References

1. Mosca L, Benjamin EJ, Berra K et al (2011) Effectiveness-based guidelines for the prevention of cardiovascular disease in women–2011 update: a guideline from the American Heart Association. *J Am Coll Cardiol* 57:1404-1423. <https://doi.org/10.1016/j.jacc.2011.02.005>

2. Towfighi A, Zheng L, Ovbiagele B (2009) Sex-specific trends in midlife coronary heart disease risk and prevalence. *Arch Intern Med* 169:1762-1766. <https://doi.org/10.1001/archinternmed.2009.318>
3. Ford ES, Capewell S (2007) Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: concealed leveling of mortality rates. *J Am Coll Cardiol* 50:2128-2132. <https://doi.org/10.1016/j.jacc.2007.05.056>
4. Ford ES, Ajani UA, Croft JB et al (2007) Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. *N Engl J Med* 356:2388-2398. <https://doi.org/10.1056/NEJMsa053935>
5. Hermes W, Franx A, van Pampus MG et al (2010) 10-Year cardiovascular event risks for women who experienced hypertensive disorders in late pregnancy: the HyRAS study. *BMC Pregnancy Childbirth* 10:28. <https://doi.org/10.1186/1471-2393-10-28>
6. Mahendru AA, Morris E (2013) Cardiovascular disease in menopause: does the obstetric history have any bearing? *Menopause Int* 19:115-120. <https://doi.org/10.1177/1754045313495675>
7. Rodie VA, Freeman DJ, Sattar N, Greer IA (2004) Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy? *Atherosclerosis* 175:189-202. <https://doi.org/10.1016/j.atherosclerosis.2004.01.038>
8. Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation. *Diabet Med* 23:469-480. <https://doi.org/10.1111/j.1464-5491.2006.01858.x>
9. American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy (2013) Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. *Obstet Gynecol* 122:1122-1131. <https://doi.org/10.1097/01.AOG.0000437382.03963.88>
10. Piepoli MF, Hoes AW, Agewall S et al (2016) 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J* 37:2315-2381. <https://doi.org/10.1093/eurheartj/ehw106>
11. Anderson TJ, Gregoire J, Pearson GJ et al (2016) 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. *Can J Cardiol* 32:1263-1282. <https://doi.org/10.1016/j.cjca.2016.07.510>
12. Heida KY, Bots ML, de Groot CJ et al (2016) Cardiovascular risk management after reproductive and pregnancy-related disorders: A Dutch multidisciplinary evidence-based guideline. *Eur J Prev Cardiol* 23:1863-1879. <https://doi.org/10.1177/2047487316659573>
13. Adams T, Yeh C, Bennett-Kunzier N, Kinzler WL (2014) Long-term maternal morbidity and mortality associated with ischemic placental disease. *Semin Perinatol* 38:146-150. <https://doi.org/10.1053/j.semperi.2014.03.003>

14. Brown MC, Best KE, Pearce MS, Waugh J, Robson SC, Bell R (2013) Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. *Eur J Epidemiol* 28:1-19. <https://doi.org/10.1007/s10654-013-9762-6>
15. Drost JT, Arpaci G, Ottervanger JP et al (2012) Cardiovascular risk factors in women 10 years post early preeclampsia: the Preeclampsia Risk Evaluation in FEMales study (PREVFEM). *Eur J Prev Cardiol* 19:1138-1144. <https://doi.org/10.1177/1741826711421079>
16. Wang IK, Tsai IJ, Chen PC et al (2012) Hypertensive disorders in pregnancy and subsequent diabetes mellitus: a retrospective cohort study. *Am J Med* 125:251-257. <https://doi.org/10.1016/j.amjmed.2011.07.040>
17. Hermes W, Franx A, van Pampus MG et al (2013) Cardiovascular risk factors in women who had hypertensive disorders late in pregnancy: a cohort study. *Am J Obstet Gynecol* 208:474 e471-478. <https://doi.org/10.1016/j.ajog.2013.02.016>
18. Fraser A, Nelson SM, Macdonald-Wallis C et al (2012) Associations of pregnancy complications with calculated cardiovascular disease risk and cardiovascular risk factors in middle age: the Avon Longitudinal Study of Parents and Children. *Circulation* 125:1367-1380. <https://doi.org/10.1161/circulationaha.111.044784>
19. Goueslard K, Cottenet J, Mariet AS et al (2016) Early cardiovascular events in women with a history of gestational diabetes mellitus. *Cardiovasc Diabetol* 15:15. <https://doi.org/10.1186/s12933-016-0338-0>
20. Kaul P, Savu A, Nerenberg KA et al (2015) Impact of gestational diabetes mellitus and high maternal weight on the development of diabetes, hypertension and cardiovascular disease: a population-level analysis. *Diabet Med* 32:164-173. <https://doi.org/10.1111/dme.12635>
21. Kim Y, Han BG (2017) Cohort Profile: The Korean Genome and Epidemiology Study (KoGES) Consortium. *Int J Epidemiol* 46:e20. <https://doi.org/10.1093/ije/dyv316>
22. Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* 120:1640-1645. <https://doi.org/10.1161/circulationaha.109.192644>
23. Moonesinghe R, Yang Q, Zhang Z, Khoury MJ (2019) Prevalence and Cardiovascular Health Impact of Family History of Premature Heart Disease in the United States: Analysis of the National Health and Nutrition Examination Survey, 2007-2014. *J Am Heart Assoc* 8:e012364. <https://doi.org/10.1161/JAHA.119.012364>
24. Veronesi G, Gianfagna F, Giampaoli S et al (2014) Improving long-term prediction of first cardiovascular event: the contribution of family history of coronary heart disease and social status. *Prev Med* 64:75-80. <https://doi.org/10.1016/j.ypmed.2014.04.007>
25. Miller EM, Hinton RB (2014) A pediatric approach to family history of cardiovascular disease: diagnosis, risk assessment, and management. *Pediatr Clin North Am* 61:187-205.

<https://doi.org/10.1016/j.pcl.2013.09.018>

26. Yogev Y, Xenakis EM, Langer O (2004) The association between preeclampsia and the severity of gestational diabetes: the impact of glycemic control. *Am J Obstet Gynecol* 191:1655-1660. <https://doi.org/10.1016/j.ajog.2004.03.074>
27. Pace R, Brazeau AS, Meltzer S, Rahme E, Dasgupta K (2017) Conjoint Associations of Gestational Diabetes and Hypertension With Diabetes, Hypertension, and Cardiovascular Disease in Parents: A Retrospective Cohort Study. *Am J Epidemiol* 186:1115-1124. <https://doi.org/10.1093/aje/kwx263>
28. Kul S, Guvenc TS, Baycan OF et al (2021) Combined past preeclampsia and gestational diabetes is associated with a very high frequency of coronary microvascular dysfunction. *Microvasc Res* 134:104104. <https://doi.org/10.1016/j.mvr.2020.104104>
29. Bonamy AK, Parikh NI, Cnattingius S, Ludvigsson JF, Ingelsson E (2011) Birth characteristics and subsequent risks of maternal cardiovascular disease: effects of gestational age and fetal growth. *Circulation* 124:2839-2846. <https://doi.org/10.1161/circulationaha.111.034884>
30. Smith GC, Pell JP, Walsh D (2001) Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. *Lancet* 357:2002-2006. [https://doi.org/10.1016/s0140-6736\(00\)05112-6](https://doi.org/10.1016/s0140-6736(00)05112-6)
31. Okoth K, Chandan JS, Marshall T et al (2020) Association between the reproductive health of young women and cardiovascular disease in later life: umbrella review. *BMJ* 371:m3502. <https://doi.org/10.1136/bmj.m3502>
32. Asgharvahedi F, Gholizadeh L, Siabani S (2019) The risk of cardiovascular disease in women with a history of miscarriage and/or stillbirth. *Health Care Women Int* 40:1117-1131. <https://doi.org/10.1080/07399332.2019.1566332>
33. Calderon-Margalit R, Friedlander Y, Yanetz R et al (2007) Late stillbirths and long-term mortality of mothers. *Obstet Gynecol* 109:1301-1308. <https://doi.org/10.1097/01.AOG.0000264548.10767.ea>

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [stable1.docx](#)